Focus for BIO 2008

• To meet equity investors who have complementary experience and skills to contribute to the growth and future value of Migco. Funds are being sought to progress its clinical trials program.
• To meet pharmacuetical companies with an interest in the treatment of migraine, and other conditions of particular interest to Migco including Alzheimer's, cognitive impairment,autism,and adhd.
• To discuss with researchers and CRO's the provision to Migco of services and studies such as animal toxicology, compound characterization, and pre-clinical use of in-vitro and animal models.

Download pdf